SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: jaybe who wrote (3914)10/29/2015 10:33:41 PM
From: mulanoon2007  Read Replies (1) of 4474
 
An interesting report in Blood from Yeung et al this week (PMID: 26500342) follows up a 2014 ASH oral presentation on the ability to predict a poor molecular response to IMA based on the presence of the KIR2DL5B allele. The ASH presentation showed how the KIR2DL5B allele was associated with an increased risk of failing to achieve MR target levels. This week’s report adds that those KIR2DL5B+ pts not achieving MMR targets on IMA also respond poorly to NIL. KIR2DL5B might prove to be a biomarker that identifies pts that could benefit from frontline PON.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News